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Abstract
The goal of this systematic literature review is to evaluate the efficacy and cost effectiveness of
pharmacogenomic testing (PGx) versus treatment as usual (TAU) in the treatment of major
depressive disorder (MDD). According to Huang & Lin (2015), MDD is characterized by
multiple signs and symptoms consisting of mood, vegetative, cognitive, and even psychotic
behaviors that may cause substantial impairment in the functioning and quality of life in an
affected individual. This literature review consisted of articles found in PubMed, Cochrane, and
PsychINFO which were extensively reviewed. Articles prior to 2008 were excluded due to the
ever-changing landscape of PGx testing. In this review, 18 articles and studies were analyzed.
This review found favorable outcomes when treatment was guided by PGx versus TAU while
examining response and remission rates. Although data varied, cost effectiveness suggested
some positive results with PGx although further investigations are needed due to limitations and
lack of studies. Despite many favorable outcomes, more evidence of the effectiveness of PGx is
needed to make a concrete recommendation that PGx guided treatment is superior to TAU.
Information in this review will help clinicians decide if this is an appropriate option for the
treatment of MDD. With continued research and ongoing studies this biotechnology is becoming
more available to the mainstream.
Keywords: depression, major depressive disorder, pharmacogenomics, pharmacogenetics,
treatment as usual, pharmacotherapy, medication, selective serotonin reuptake inhibitors,
antidepressant, psychiatry and Patient Health Questionnaire (PHQ-9)

PHARMACOGENOMIC TESTING IN DEPRESSION TREATMENT

5

Does the use of Pharmacogenomic Testing Improve Depression Outcomes Better Than
Treatment as Usual?
Introduction
According to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5;
American Psychiatric Association, 2013), “major depressive disorder (MDD) is characterized as
a serious illness that causes a person to feel deeply sad (or wholly absent of feeling) most of the
day, nearly every day, for at least two weeks”. According to Greenberg, Fournier, Sisitsky, Pike,
& Kessler (2015), depression is one of the most burdensome illnesses worldwide and contributes
to many unfavorable side-affects leading to functional impairment and disability. Depression is
the leading cause of disability in the United states with an average of 400 million disability days
each year. According to Greenberg at al. (2015), this is a much higher number than other mental
and physical conditions.
Pharmacogenomics is the study of how genes affect an individual’s response to
medications. Pharmacogenomic testing can be utilized to see what medications may be the most
effective for a patient with the least amount of side effects. Though the utilization of PGx
appears beneficial in choosing a medication tailored to a patient’s specific genes, the clinician
should continue to keep age, lifestyle, side effects, cost, and comorbid factors in mind while
using pharmacogenomics. MDD continues to be a significant health condition that impacts
people regardless or devoid of age, race, or gender. Comorbidities are often associated with
depression which can make appropriate management difficult. The goal of the clinician is to treat
these patients with the best possible medication choice while mindful of side effects, cost, and
outcomes.
This review will focus on medication management rather than other treatment modalities.
Treatment as usual (TAU) with medication management is usually based on practice guidelines
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and the clinicians own experience with certain medications that they believe will help control
current symptoms. The purpose of this article is to evaluate whether PGx demonstrates improved
clinical outcomes compared to TAU.
Statement of the Problem
Treatment of depression remains a difficult issue in primary care as well as psychiatric
medicine. Many of these patients require multiple medication trials prior to finding a drug that
works to control their symptoms without causing unfavorable side effects. This process may
cause prolonged suffering with depression as well as a decrease in quality of life and
productivity. The cost and time strain of attempting multiple medications continues to be a
burden on the patient as well as the medical community.
Studies on pharmacogenomic testing for MDD are needed to demonstrate which
medications may have higher efficacy and lower cost for both the patient and health care
community. Medications are uniquely metabolized based on multiple genetic variants which
pharmacogenomic testing can help identify. One consideration to remember while reviewing this
paper is that many medications are not able to be analyzed with metabolism and genetic
variances at this time, therefore only medications included in the pharmacogenomic testing
databases are explored.
Research Questions
In patients with MDD, are medications guided by pharmacogenomic testing in the
treatment of MDD more effective in achieving response and remission of symptoms compared
with TAU based on depression assessment scales?
In patients with MDD, does medication management guided by pharmacogenomic testing
improve cost effectiveness in the management of disease compared to TAU?
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Research Methods
To prepare for this scholarly project multiple databases were searched using electronic
databases which included PubMed, Cochrane, and PsycINFO to help find a wide array of topics
relating to the treatment of MDD. The primary focus of the search was depression,
pharmacogenetic/pharmacogenomic testing, and treatment in adults. In the research I utilized the
following phrases, keywords, and MeSH terms: depression, major depressive disorder,
pharmacogenomics, pharmacogenetics, treatment as usual, pharmacotherapy, medication,
selective serotonin reuptake inhibitors, antidepressant, psychiatry and Patient Health
Questionnaire (PHQ-9). The databases were further searched to narrow the topic down to major
depressive disorder. Due to limitations in the number of studies found in the search, articles
published from 2008 to the present were utilized. Several studies were excluded as they did not
focus solely on MDD and contained a broader analysis of depression treatment in general.
Articles utilized in this project contained meta-analyses, systematic reviews, randomized
controlled trials, and cohort studies.
In this project the population of patients reviewed had a diagnosis of MDD. The studies
evaluated were also specific to the adult population which included patients 18 years of age or
older. Exclusion criteria included other mental conditions that may contribute or exacerbate the
symptoms associated with MDD.
There are many different variables that need to be considered when treating MDD such as
cost, side effects, comorbid conditions, and compliance. With the ever-growing amount of
medications to treat this disorder along with the growing technology associated with PGx, it is an
exciting time to work in a field that is so rapidly changing. Educating clinicians on these changes
in healthcare will remain a top priority in the treatment of this debilitating disease.
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Literature Review
A review of the literature has shown many positive outcomes associated with the use of
PGx testing. Although there are limitations in each study, moving forward with
pharmacogenomic testing should illuminate possible treatments that may have not been
considered if the patient was receiving TAU.
Pathophysiology of Major Depressive Disorder
The Diagnostic and Statistical Manual of Mental Disorder (5th ed.; DSM-5; American
Psychiatric Association, 2013) is widely used by clinicians and researchers alike to classify
specific mental disorders. According to the DSM-V, Major Depressive Disorder (MDD) is
diagnosed by having five out of the following nine symptoms. Depressed mood most of the day
which occurs nearly every day, diminished interest or pleasure in almost all activities, significant
weight loss categorized as 5% of body weight in a month, insomnia or hypersomnia,
psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness or
excessive inappropriate guilt, diminished ability to think or concentrate, or recurrent thoughts of
death/suicide or suicide attempt. Five of these nine symptoms must be present nearly every day,
during a two-week time frame. These symptoms need to cause significant stress with social and
occupational impairment. Also, these episodes may not be attributable to the physiologic effects
of a substance or another medical condition (American Psychiatric Association, 2013).
According to Rot, Mathew, & Charney (2009), one in five Americans will experience an
episode of MDD at least once in their life although most suffer more than one episode. In the
past, most studies have focused on the monoamine neurotransmitters of dopamine and
norepinephrine. This article discusses the multitude of possible attributing factors to the
development of MDD which includes genetics, events from childhood, stress, structural and

PHARMACOGENOMIC TESTING IN DEPRESSION TREATMENT

9

functional abnormalities of the brain, abnormal function of the hypothalamic-pituitary axis, and
interactions between genes and the environment a person is exposed to. The authors conclude
that future research should focus more on individualized medicine with an emphasis on
medication metabolism and independent genetic markers that may predispose a person to this
condition.
In the meta-analysis by Verdujin et. al (2015), the involvement of different
pathophysiological mechanisms such as inflammation, hypothalamic-pituitary axis, neurotrophic
factors, and vitamin D are examined to see if their dysregulation is contributory to the diagnosis
of MDD as well as the progression of MDD. This meta-analysis selected participants from the
Netherlands Study of Depression and Anxiety (NESDA). The study focused on 2,831 subjects 18
to 65 years old who were either healthy controls or diagnosed with varying stages of MDD. The
people in these studies were allocated from multiple different clinical practices such as
psychiatry and family practice. The results suggested that mechanisms involved in the etiology
of depression are not associated with the clinical progression of MDD. Strengths of this analysis
were the large population of well diagnosed patients with variable socioeconomic status. Results
showed a trend of increased CRP (p=0.090), increased cortisol (p=0.025), and decrease in
Vitamin D (p<0.001) with the diagnosis of MDD, but the extent of change in these values were
not associated with the severity and chronicity of the disease. No trend was seen between brain
derived neurotrophic-factor (BDNF) and MDD in this meta-analysis. Results also showed that
women who were active smokers with a lower education compiled with chronic diseases used
selective serotonin reuptake inhibitors (SSRI’s) and anti-inflammatory medication more
frequently (Verdujin, 2015). Limitations were such that complications and other comorbidities
were not discussed or evaluated in this article. It was also noted that samples retrieved were
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either from a blood draw or saliva sample which comes from the periphery. This may not
accurately demonstrate what process is taking place in the central nervous system (CNS) and
may not represent these values properly, although most studies have examined peripheral DNA.
Lastly, there are multiple models to stage MDD and may not be congruent with other studies that
have utilized different staging models.
In the next article by Villanueva (2013) the goal was to evaluate studies that focus on the
neurogenesis (growth and development of the nervous system) in those with MDD. The
information in this article was collected over a span of twenty years with the purpose to
hopefully help find new therapies and diagnostic tools to manage MDD. Different gene and
protein expression that may affect the pathophysiology of MDD were examined. The evidence in
this article supports the theory that disturbed neurogenesis is a factor in MDD. Although many
circumstances such as traumatic events, chronic disease, neurological/endocrine issues, and
substance abuse can contribute to the development of MDD, genetic factors have been linked to
the diagnosis. Some of the genetic issues associated with MDD discussed in this article were low
serum levels of brain-derived neurotrophic factor, micro RNA which helps regulate the control
of genes, stress hormones of the HPA axis, inflammation, and gut microbiota (Villanueva, 2013).
Controversial issues in this review include whether neurogenesis is the basis of the disease or if it
is a response that may be induced by antidepressant treatments.
In an article by Fabbri and Serretti (2015), the complex nature of specific genes and
pathways that may affect the approach to treatment of MDD can be partially evaluated by
pharmacogenomics. The article discusses correlations between genes such as SLC6A4, HTR2A,
BDNF, GNB3, FKBP5, ABCB1, and the cytochrome P450 system. The authors evaluated
previous studies that have shown promising outcomes when pharmacogenomic testing is used to
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detect different genes and pathways that may affect the medications mechanism of action. It is
noted that gene studies have an advantage over TAU as PGx is focused on a biology supported
hypothesis. With continued research it is hypothesized that pharmacogenomic testing will
become mainstream in the treatment of MDD. Limitations include the vast number of genes not
evaluated that may play a role in this disease.
Pharmacogenomic testing to aid in the treatment of MDD
In the meta-analysis performed by Rosenblat, Lee, and McIntyre (2018), the authors
focused on two open-labeled and four blinded random controlled trials (RCT’s). The quality of
the studies in the meta-analysis were assessed using the Cochrane Handbook for Systematic
Review of Interventions. All the studies included were funded at least partially by companies
that were manufacturers of different pharmacogenomic tests to direct treatment. Response and
remission rates were taken into consideration although one of the studies did not report response
and another did not report remission. They reported response rates on 799 adult patients and
remission rates on 735 adult patients. The Hamilton Rating Scale for Depression (HAMD-17)
was used to assess the response and remission rates as well as safety and tolerability. Response
to treatment was defined as a decrease in initial HAMD-17 score by 50%. Remission was
defined as a HAMD-17 score of less than eight. The results aligned with the initial hypothesis
supporting treatment outcomes using pharmacogenomic testing. The guided group of patients
had a response rate of 50% compared to the unguided group at 36%. The pooled relative risk
(RR) for treatment response comparing guided versus unguided treatment was 1.36 or a 95%
confidence interval in favor of guided treatment and a (p=0.0006). The pooled RR for remission
was 1.74 or 95% confidence interval and a (p=0.02) which demonstrates statistical significance.
The remission rates of the guided treatment group were 40% when compared to the unguided
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group at 25%. It was noted that different brand name of pharmacogenetic testing displayed
different response and remission rates. NeuroIDgenetix and CNSDose showed a significant
positive effect towards guided therapy whereas Genesight and Neuropharmagen did not show
any difference between guided and unguided therapy. Some limitation noted in this metaanalysis were that multiple studies were funded by companies who manufacture the
pharmacogenomic tests. Other things of note were that most studies were not blinded or
controlled, the lack of heterogeneity, the use of different genotyping kits, and the small number
of studies and inclusion of open-label cohort studies. All these aspects may potentially decrease
the reliability of the reported results (Rosenblat, Lee, & McIntyre, 2018).
In a 12-week, double blind, parallel, multi-center randomized controlled trial by Perez et
al. (2017), 316 adult subjects who were diagnosed with MDD were evaluated. The clinical global
impression scale (CGI-S) was used to identify patients with a score greater than 4. The scale
ranges from 1 meaning normal or no disease, to 7 which is related to the most severe form of
disease. The trial evaluated how effective the use of PGx was when utilized in medication
management for treatment of MDD. Randomization was used which either gave the prescribing
psychiatrist access or no access to PGx results. The PGx utilized in this study was
Neuropharmagen. There were 155 patients who received PGx guided treatment while 156
received treatment as usual. The endpoint of the 12-week study was to achieve a response that
was sustained. Unfortunately, a sustained response was not seen within this study time frame
with a (p=0.4735). Of note, the PGx guided treatment group did have a higher rate of response to
medication at 47.8% compared to the TAU group at 36.1%. This demonstrated a (p=0.0476) with
a 95% confidence interval. Patient who had previously attempted at least one medication for
depression prior to this trial did have more positive outcomes. This is likely due to being
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prescribed a medication that they have not tried in the past which decreased the room for error.
Side effects were lower at six weeks and remained lower at twelve weeks for the PGx group as
well. Limitations of this study included multiple patients who had previously failed one or more
antidepressant therapies, therefore decreasing the odds on receiving an appropriate medication.
Also, a longer study time may have been able to identify a sustained response to medication. The
population size was also small, and a larger population may be needed to appropriately analyze
results of such a study.
In an 8-week, single-blinded, and randomized clinical trial by Han et al. (2018), the
effectiveness of PGx vs. TAU was evaluated in 100 Korean patients. All patients were randomly
placed in either the PGx or TAU group. The patients were at least 20 years old and diagnosed
with MDD by experienced psychiatrists using the DSM-5 for diagnosis criteria. Middle-aged,
married, and unemployed women were the highest demographic in both groups. Patients with
other psychiatric conditions were excluded from the study. Also, patient with substance abuse,
neurological impairment, or pregnancy were not entered into the study. Inclusion criteria were:
1) Patients needed to currently be on antidepressant therapy for at least six weeks which included
mono or polytherapy; 2) Patients needed to score a 3 or greater on the CGI scale; 3) Patients
must be deemed intolerant to their current antidepressant use. All participants underwent saliva
sampling prior to the study which was evaluated by Neuropharmagen which is a
pharmacogenetic analyzing system. Complete medical/neurological examinations were
completed on all patients prior to entering the study. Neuropharmagen was able to analyze 22
antidepressants, 13 mood stabilizers, 6 anti-anxiety medications, and 5 other neuropsychotropic
drugs. They were categorized by colors, green being more likely for positive response, red likely
for intolerance or negative response, yellow needing to be closely monitored, and white which
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had no genetic variants discovered at that time. At the beginning of this study patients were
randomized by a computer generator with a 1:1 ratio to be placed either in therapy guided by
PGx or TAU. Based on randomization the patient was either placed on a PGx or a TAU
medication based on medical history and provider preference. Patient’s continued to take
benzodiazepines and sleeping aides as usual. The primary endpoint was the mean change of the
total score of the in 17-item Hamilton Depression Rating Score (HAMD-17) from the patient’s
baseline compared to measurement at the end of treatment. The secondary endpoint consisted of
response and remission rates. Response was defined as a 50% reduction in HAMD, and
remission was defined as a HAMD score of <7. Patients in both groups had a moderate to severe
HAMD rating at the beginning of the study (23.8±4.8). The study began with 52 individuals in
the PGx group, and 48 in the TAU group. The PGx group ended up with 39 completing the study
and 30 in the TAU group completing.
Results of the study by Han et al. (2018) were in favor of pharmacogenomic testing with
an increased change in the HAMD score in the PGx guided patients by a 4.1 difference
(p=0.010). The response rate was substantially higher based on the HAMD in the PGx group
compared to TAU with a 28.1% difference (p=0.014). The remission rate also reported higher
with PGx guided therapy with a 19.9% difference, although did not prove statistical significance
(p=0.071). Limitations were that the study was only single blinded which gives room for bias.
The study was limited to each subject receiving one antidepressant even if an adverse event
occurred, and the sample size was small.
In the open-label, eight-week study by Hall-Flavin (2013), pharmacogenomic testing was
explored to see if gene guided medication management of MDD was beneficial. The open-label
study was divided into two groups. In the first group (unguided), the pharmacogenomic profiles
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were not provided to the treating clinician until the study was complete. In the second group
(guided), the pharmacogenomic data was provided to the clinician to help guide medication
decisions in the patient’s treatment. Three depression screens were used in this study consisting
of the HAMD-17, QIDS-16, and PHQ-9. Results were collected at baseline and then at weeks
2,4, and 8. The results demonstrated higher outcomes in the pharmacogenomic guided group
based on the results of all three screening tools. Some of the participants in the unguided group
were treated with medications that would not have been recommended according to the
pharmacogenomic profile. As a result, this group yielded the lowest improvement in scores.
Participants in the guided group with a medication congruent with their pharmacogenomic
profile had the greatest improvement. HAMD-17 and PHQ-9 reached statistical significance with
PHQ-9 (p=<0.001) and HAMD-17 (p=< 0.001). Not only did the scores decrease more with the
guided group, but they decreased faster at 2,4, and 8 weeks. One limitation of this study was the
high rate of participants dropping out of the guided group. This could have increased the number
of participants scoring poorly on screening tools. Also, due to the design of the study,
participants in the guided group knew the results of their genotyping which may have caused a
placebo effect or influenced their scores. With that said, after eight weeks the guided group had a
10.9-point decrease in their HAMD-17 score compared to 6.5 of the unguided group. The 4.4point difference exceeds the 3-point standard for clinical significance set by the National
Institute of Clinical Excellence (Hall-Flavin, Winner, Allen, Carhart, Proctor, et. al 2013).
Cost Effectiveness of Pharmacogenomic Testing
An article by Maciel, Cullors, Lukowiak, & Graces (2018) was a review of two studies.
The first is by Greenberg et al, (2015), and is titled “The economic burden of adults with major
depressive disorder in the United States”. The second is by Bradley et al. (2017) and is titled
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“Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression
and anxiety: a randomized clinical trial demonstrating the clinical utility”. The annual economic
burden of adults with MDD as studied by Greenberg was $30,949 compared to the control group
at $5,744 in the year of 2012. This was measured in U.S. dollars. This analysis compared the
costs that were associated with “red bin” patients (medications that are identified as problematic)
to “green bin” patients (use as directed medications) and “yellow bin” patients (use with caution)
based on the results of pharmacogenomic testing. The “green bin” guided group had a 1.21 net
reduction in disability days per months which averaged a saving of $1,453.56 annually. The
model showed a potential yearly cost savings of $3,962 per patient with guided treatment per
NeuroIDgenetix after adding the $2,000 cost of the genetic testing. They measured the efficacy
of treatment with pharmacogenomic guided treatment in a variety of settings outside of general
psychiatric care. In conclusion, this model predicts an average savings of $3,962 per year in U.S.
dollars when treatment is guided by pharmacogenomic testing. Some limitations are that the
funding of initial studies is not known, the brands of genotype testing kit used, and unknown
comorbidities of patients. The study by Bradley et al. had 685 participants in various settings.
The researcher’s results demonstrated a significantly higher remission rate of 35% versus 13%
and (p=0.02) for the guided treatment group compared to the treatment as usual (TAU) group.
There was also a much higher response rate with the guided group 73% versus 36%, (p=0.001)
compared to TAU. Limitations include that the data published in peer reviewed journals where
efficacy and cost effectiveness were evaluated by two different sources which may skew results.
Also, quality of life is not taken into consideration while analyzing the noted studies.
The next study conducted by Peterson et al. (2017) looked at the efficacy, harm, and cost
effectiveness of PGx versus TAU for MDD treatment. The study included two RCT’s, five
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controlled cohort studies, and six modeling studies. The modeling studies primarily focused on
women in their mid-forties with few comorbidities. The RCT’s and controlled cohorts focused
on adults with MDD and allowed any manufacturer of pharmacogenomic testing kits to be
allowed in the study. There was no restriction on timing of the study, settings, or design. Agency
for Healthcare Research and Quality (AHRQ) was the guide used to measure the strength of the
evidence as low, moderate, high, or insufficient. StatsDirect software was utilized to pool the
gathered data using a random-effects model. Statistical heterogeneity was measure by a
Cochrane’s Q test. Multiple genotype testing kits were assessed including CNSDose, ABCB1,
and Genesight. Response was measured as a 50% reduction in the HAMD score. Remission was
achieved with a HAMD < 10. CNSDose was the only genotype test that significantly improved
remission rates with one in every three tested remitting within 12 weeks. CNSdose also reduced
the number of patients taking sick leave 15% versus 4%, (p=0.0272) and reduced medication
intolerability with a 95% CI. ABCB1 also had one in three patients remitting in a shorter period
of 5 weeks but did not account for tolerability, quality of life, functional status, and side effects
of the medication and therefore was not found to be statistically significant. Genesight did not
improve response or remission rates (CI=0.56) to a statistically significant value, nor was
tolerability accounted for. Cost effectiveness is unknown, and evidence is low due to the low
number of RCT’s with a lack of directly observed financial saving. With pharmacogenomic
testing for MDD treatment being in its early years of research, further studies will need to be
completed to assess the potential costs or savings associated with this service. Although the
study proved inconclusive, it does show somewhat promising results for CNSDose in the
treatment and time of remission in patients with pharmacogenomic guided therapy. Limitations
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include the number of RCT’s reviewed, the small patient demographic, and the unknown
comorbidities of selected patients.
In a study by Benitez, Cool, and Scotti (2018), the authors evaluated administrative
claims by health plan members who were treated for psychiatric conditions with PGx vs. TAU.
Costs were defined as any payment or reimbursement made for the treatment of psychiatric
conditions which included depression, anxiety, bipolar, premenstrual dysphoric disorder, posttraumatic stress disorder, obsessive-compulsive disorder, and schizophrenia. This included
prescriptions, office visits, inpatient, and outpatient services. They used a major healthcare
insurance provider which consisted of over 25 million members. Payments were evaluated for 24
months, pre and post treatment. Although only records were reviewed, plan member records
evaluated had to be at least 18 years old and on a commonly prescribed psychotropic medication
starting within the past 180 days and without other known history of psychotropic medication
use. These could be members who received TAU or PGx. Statistical significance was evaluated
by measuring the pre and post treatment cost controlling demographics and comorbid conditions.
They analyzed 205 members treated by PGx and 478 with TAU. There was no significant
difference in the cohorts when age and gender were observed. Although over the period studied
the healthcare costs in both groups did rise, the TAU increase was higher at $23,132 versus
$17,627 (p=0.0004). The cost of the PGx test was taken into consideration during these analyses.
It was noted that the reduced spending was mostly saved by a decrease in outpatient services
received. Once broken down with a focus on depression, costs did continue to rise for both
groups, but higher in the TAU group at $24,791 vs $18,741 (p=0.0090). This included 94
members with PGx and 229 with TAU. The savings were related to outpatient, inpatient, and
pharmacy costs. Limitations of this study included not knowing the brand of PGx test being
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utilized and no way of knowing if the prescribers followed the PGx recommendations since only
the administrative claims could be reviewed. The course of treatment was also not well known.
Discussion
These studies have shown some promise in the use of pharmacogenomic testing for the
treatment of MDD. MDD may affect a person in many different aspects of their life whether it be
emotionally, physically, or financially. As the use of pharmacogenomic testing in the treatment
of MDD continues to be explored, the very complicated disease process of MDD that may stem
from multiple variances in genes must be considered. After reviewing the literature, the use of
PGx may have a positive impact in the treatment of MDD when compared to TAU. As advances
continue, this will help guide treatment and reduce the cost associated with the treatment and
management of MDD.
When comparing the studies on effectiveness of PGx guided treatment, response rates
were higher in all studies for the guided therapy groups. Also, remission was higher with guided
therapy, but in most studies, remission was not sustained due to the short study periods being
analyzed.
Pathophysiology of Major Depressive Disorder
In the articles discussing the pathophysiology of MDD, it is a common theme that
neurogenesis and genetic biomarkers play a role in the development and/or progression of MDD.
Although this can be agreed on, the exact science of different biomarkers along with
environmental factors remains an area of uncertainty. Continued research will reveal different
mechanisms that play a role in the disease process.
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In the meta-analysis by Verdujin et. al (2015) no link between BDNF and MDD was
established, but in contrast, the review by Villanueva (2013) discussed the link between low
serum BDNF and MDD. Further investigational studies are needed to assess this more
thoroughly.
Also, the lack of studies in this project which address lifestyle/environmental factors
contributing to the diagnosis and/or progression of this disease makes it hard to fully evaluate all
components that may lead to MDD.
In patients with major depressive disorder (MDD), are medications guided by
pharmacogenomic testing in the treatment of major depressive disorder more effective in
achieving response and remission of symptoms compared with TAU based on depression
assessment scales?
The articles evaluated showed positive outcomes in many aspects of treating patients with
pharmacogenomic guided treatment. In the article by Rosenblat, Lee, and McIntyre (2018), the
study did replicate the hypothesis that the effects of PGx would have more favorable outcomes
when the patients pharmacodynamic and pharmacokinetic profiles were known by the provider
prescribing the medication. They also noted that in many studies patients who are aware of PGx
may have an enhanced placebo effect because they feel that they are getting the best possible
medicine to treat their disease. Their analysis did overall favor PGx with reported higher
response and remission rates as seen in table 1 and table 2.
In the open label study by Hall-Flavin et al. (2018) they discussed the key elements that
would be required to make an impact and possibly change the way psychiatric care is delivered.
The three key elements were “(a) pharmacogenomic information must be predictive of those
individuals whose specific treatments are likely to be intolerable or no efficacious; (b)
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pharmacogenomic information must be easily integrated into clinical workflow; (c) it must
effectively guide treatment decision, resulting in improved clinical outcomes” (p. 543-544). In
this study by Hall-Flavin et al. (2018) all three elements discussed above were met. This is a
great success for the future of pharmacogenomic testing in the psychiatric world.
Given that most of the studies reviewed were conducted over 8-12 weeks, Perez et al.
(2017) notes that longer follow up times in these studies may help confirm that response to
medication is sustained. As many of these medications take weeks to be effective, it is hard to
judge if the response is sustained in such a short time frame. The study by Hall-Flavin et al.
(2018) did discuss how placebo affect could influence an earlier response which would be seen
in these shorter timeframes.
In an article by Kitzmiller, Groen, Phelps, & Sadee (2011), the importance of gene testing
for multiple scenarios was discussed. For example, patient with the polymorphism 5-HT 2A
should receive Citalopram for their treatment due to higher reported side effects from different
SSRI’s. This is just one instance of progress being made in this new field of research. With that
said, the study by Hall-Flavin et al. (2018) demonstrated that the guided treatment group had
more CYP2D6 poor metabolizers than did the TAU group. The significance of metabolizers in
the PGx versis TAU groups may skew results based on the treatment group in which they fall
into.
It is important to remember that genes are not the only variability that could affect the
tolerability of a medication. According to Perez et al. (2017), the response and tolerability may
be affected by multiple other aspects of the patient such as medication-medication interaction,
lifestyle, drug use, and other environmental factors.
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The article by Fabbri & Serretti (2015) evaluated genes such as SLC6A4, HTR2A,
BDNF, GNB3, FKBP5, ABCB1, and the cytochrome P450 system whereas the study by
Verdujin et. al (2015), looked at the involvement of different pathophysiological mechanisms
such as inflammation, hypothalamic-pituitary axis, neurotrophic factors, and vitamin D. When
evaluating the effectiveness of PGx, we can see it is important to know what is being measured
as different studies have evaluated different pathophysiology of the disease.
According to Rosesnblat, Lee, & McIntyre (2018), it is important to remember that these
studies only reported “proprietary pharmacokinetic polygene pathway pharmacogenetic
interpretive formula” (p-488). As this field continues to grow it will be important to look at other
genetics such as CYP450, serotonin receptor, transporter genes, and p-glycoprotein genes. This
will only help to improve the efficacy of pharmacogenomic testing and hopefully help bring it to
the forefront of psychiatric care. This article again focused on the complex nature of PGx testing
which was outlined in other articles as mentioned above.
In the meta-analysis performed by Rosenblat, Lee, and McIntyre (2018), the PGx
Neuropharmagen did not demonstrate a statistically significant difference in response or
remission rates vs. TAU, whereas the 12-week, double blind, parallel, multi-center randomized
controlled trial by Perez et al. (2017) demonstrated statistically significant results with treatment
guided by PGx vs. TAU. Therefore, it is important to remember that the limitations of these
studies may have a profound effect on the outcome and that the lack of homogeneity between
different PGx which may demonstrate much different results.
According to Han et al. (2018), one must consider that over 40 pharmacogenomic testing
kits are available for use. They go on to note that many of the recommendations from the four
different PGx kits that were used in their trial had substantial differences in what genes and
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variants were tested. The algorithms to predict the drug-gene interactions were also noted to be
quite different. With the noted results above, continued studies on efficacy of certain PGx kits
must be evaluated. The importance of reproducibility will greatly impact the likelihood of
psychiatrists and providers acknowledging these products as reliable and accurate. With that
noted, the results were supportive of increased response and remission rates with the use of PGx
testing as seen in table 1 and table 2.
In an article by Ikediobi, Shin, Nussbaum, & Phillips (2009), the knowledge clinicians
have about pharmacogenomic testing has a significant influence in the ability to make the
integration of this practice into the clinical setting successful. Many clinicians are currently not
comfortable or confident with the use of such testing, therefore as studies continue to show
positive outcomes, educating providers must occur in order to optimize outcomes of patients
diagnosed with MDD.
It is clear the lack of education regarding PGx guided treatment within the healthcare
community continues to slow the process of mainstreaming this new tool into clinical practice.
While multiple studies continue to demonstrate the improvement of response and remission of
MDD with the use of PGx, we should continue to see this instrument show a greater presence in
everyday healthcare. PGx treatment in cancer has shown great promise and with continued
success it will be one of the most useful tools in treating MDD.
In patients with MDD, does medication management guided by pharmacogenomic testing
improve cost effectiveness in the management of disease compared to TAU?
In the study by Benitez, Cool, & Scotti (2018), the cost savings of PGx could be
substantial in patients with complex comorbidities as well as polypharmacy issues. Guiding
treatment to decrease side effects and increase tolerability while considering comorbid diseases
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and other medications utilized can prevent hospitalization, outpatient follow-ups, and pharmacy
costs.
In the article by Kitzmiller, Groen, Phelps, & Sadee (2011), when providers have access
to the status of their patients’ genetics, being able to predict response to medications becomes
more feasible which in turn leads to better drug efficacy, fewer side effects, and a better cost to
benefit ratio.
According to Han et al. (2018), the economic benefits of PGx should be considered as an
important factor while implementing this new tool into clinical practice. With the favorable
results of his study and multiple other meta-analyses, substantial reduction in healthcare
spending could be seen by utilizing this technology.
According to Groessl, Tally, Hillery, Maciel & Garces (2018), a large portion of patients
do not respond to initial treatment prescribed for MDD and have decreased productivity and a
higher rate of suicide. The trial and error of treatment as usual can delay proper care by days,
months, or even years. The delays can be directly related to an increase in patients suffering,
higher medical costs, and a higher risk of suicide. Being able to possibly identify a medication
that may be effective is critical in decreasing the cost of healthcare that grows as a patient
continues to struggle with MDD. Groessl, et al. (2018) states, “growing evidence supports the
use of pharmacogenetic-guided treatment to shorten the length of time required to identify an
effective treatment regimen” (p.731). Their study also evaluated care over three years which
identified reduced costs associated with treatment of MDD as well as higher effectiveness.
Although many different variables must be taken into consideration when looking at the
cost effectiveness of PGx in the treatment of MDD, the above studies have demonstrated
multiple scenarios with improved economic impact when utilizing this service. Replication of
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studies with similar results should help pave the way to moving forward with the implementation
of PGx guided treatment into mainstream medicine.
Currently many commercial insurances do not cover any form of pharmacogenomic
testing for the treatment of MDD. Current medical practices continue to rely on TAU and
provider preferences, but continued research and studies of MDD should help move this new
practice forward.
Applicability to Clinical Practice
The goal of this project was to evaluate the use of pharmacogenomic testing in the
treatment of MDD compared to TAU. Another goal was to also evaluate the cost-effectiveness of
PGx. As we strive to make mental health topics less taboo, the treatment of these diseases will
surely increase. With new advances such as PGx, genetically guided treatment will continue to
be evaluated and hopefully show positive outcomes for those suffering from such conditions.
Treatment of MDD can be quite challenging whether it be by psychiatry or family
medicine. Being able to review an individual’s genetics and how they may react and/or
metabolize a drug should eliminate time and cost while improving the patient’s mental health.
Many of these studies show that utilizing PGx has shown greater improvement in depression
rating scores, less cost associated with treatment, and improved quality of life.
Exploring and testing the effects of BDNF, cortisol, inflammatory markers, and Vitamin
D levels have revealed some common links between a person’s health and MDD. As PGx
continues to evolve it is likely that we will see more studies evaluating the CYP450 system to
better understand the metabolism of many of these drugs. As some insurance companies are now
covering some or all costs of these tests, it is presumed that they will become more readily
available and providers will receive proper education on the utilization of PGx.
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Table 1.
Response rates of PGX vs. TAU in the treatment of MDD

Response Rates: PGx vs. TAU
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Roseenblat et al. (2018)
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Han et al. (2018)
Response/TAU %

Note: Data for this chart came from Rosenblat, Lee, and McIntyre (2018) and Han et al. (2018).
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Table 2
Remission rates of PGx vs. TAU in the treatment of MDD
50

Remission Rates: PGx vs. TAU
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Remission TAU %

Note: Data for this chart came from Rosenblat, Lee, and McIntyre (2018) and Han et al. (2018).
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